Last reviewed · How we verify
LEO 29102 Plus Betamethasone Dipropionate — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
LEO 29102 Plus Betamethasone Dipropionate (LEO 29102 Plus Betamethasone Dipropionate) — LEO Pharma.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LEO 29102 Plus Betamethasone Dipropionate TARGET | LEO 29102 Plus Betamethasone Dipropionate | LEO Pharma | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LEO 29102 Plus Betamethasone Dipropionate CI watch — RSS
- LEO 29102 Plus Betamethasone Dipropionate CI watch — Atom
- LEO 29102 Plus Betamethasone Dipropionate CI watch — JSON
- LEO 29102 Plus Betamethasone Dipropionate alone — RSS
Cite this brief
Drug Landscape (2026). LEO 29102 Plus Betamethasone Dipropionate — Competitive Intelligence Brief. https://druglandscape.com/ci/leo-29102-plus-betamethasone-dipropionate. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab